2026 Legal Alert: Law Offices of Timothy L. Miles

As of March 2026, our firm is tracking two major corporate accountability trends: the surge in Fume Event Lawsuits involving Airbus “bleed air”and Zepbound and Vision Loss along with other GlP-1 Drugs. Whether it’s toxic cabin air or pharmaceutical negligence, we are providing the latest evidence for victims seeking justice.

Introduction to Zepbound and Vison Loss: Critical Patient Updates

The Zepbound and vision loss nighmare continues with attorneys fielding calls from patients taking Zepbound (tirzepatide) who have suffered serous Zepbound vision problems including the loss of vision in one eye from a detaiched retina.  Serious vision healh concerns have skyrocked recently regarding potential Zepbound vision side effects, prompting individuals who took Zepbound and suffered vision loss to file a Zepbound vision loss lawsuit against the drug’s manufacturer, Eli Lilly and Company alleging that the company failed to warn patients or doctors about these very serious Zebpound eye side effects.

Specifically, there have been cases of a condition called nonarteritic anterior ischemic optic neuropathy (NAION) being reported among patients taking this medication. This has prompted further investigation into whether there is a link between tirzepatide and serious eye complications which current clinical trials and an abundance of adverse event reports by patients have confirmed.

In this critical Zepbound and vision loss update we will inform you on the status of the Zepbound vision loss lawsuit as well as address the numerous Zepbound vision prolems afflicting patients including, unfortunatley, permanent vision loss on one eye.

If you are a patient taking Zepbound, please read this carefully as this is a very serious and debilitating vison health issue that may Zepbound uses are completely unaware off and need to undestand the vital question:

Is the weight loss worth the loss of an eye.

Top 25 Class Action lawyer and AV Preeminet Rated Judical Version (based on confidential endorsements by members of the juduciary) ad for free case evaluation in zepbound and vision loss

Current Status of the National MDL (March 2026)

  • Case Count: There are now 3,363 pending cases in the federal MDL, which is actually shrinking as meritless claims are purged.
  • Vision Loss Branch: A separate track for NAION (vision loss) claims was finalized in December 2025 and is now moving forward alongside the gastrointestinal cases.
  • Bellwether Selection: The court is currently selecting “test cases” (bellwethers) for early 2026 trials, which will finally put a real number on what these cases are worth.

The “Gold Standard” Diagnostic Tests

The court, under Judge Karen S. Marston, now requires one of the following specific tests to move a case forward:
  • Gastric Emptying Scintigraphy: The primary “gold standard” test where a patient’s digestion is tracked via a radio-labeled meal.

Insufficient Evidence (What to Avoid)

  • You should be advissed that common scans like CT scans, MRIs, and endoscopies are generally insufficient for the MDL.

 Zepbound and Blurry Vision vs. NAION Update

  • The Legal Reality: New 2026 lawsuits (MDL No. 3163) argue that this “blurriness” can actually be an early sign of NAION(non-arteritic anterior ischemic optic neuropathy), also called an “eye stroke,” which leads to permanent blindness.

Glucagon-like peptide-1. Close-up of Cell membrane lipid bilayer with Receptor GLP1R. illustration.

Symptoms of NAION

  • Decreased color vision

The American Academy of Ophthalmology states the following on the clinical features of NAION:

Symptoms. NAION typically presents as an acute, monocular, painless loss of vision. Although bilateral presentation is rare, it can occur in the setting of severe blood pressure fluctuation due to surgery, hemodialysis, or excessive blood loss. Ocular discomfort, headache, and periocular pain ]are not typical but have been reported in 10% of pa­tients. Presence of pain should prompt investigation for alternative causes of the vision loss.

Signs. Visual loss is usually less severe in NAION than in arteritic anterior ischemic optic neuropathy (AAION). The absence of light perception is rare in NAION and, if present, should lead the clinician to suspect AAION. At presentation, 50% of NAION patients have VA better than 20/64, and 66% have better than 20/200. Some NAION patients may have normal VA.

The typical visual field defect in NAION is inferior altitudinal vision loss. However, other patterns may be detected, including inferior nasal loss or central, cecocentral, and/or arcuate scotomas.

As in other types of optic neuropathy, dyschromatopsia and relative afferent pupillary defect may be present in NAION. The degree of dyschromatopsia in NAION is proportionate to the VA loss, unlike in optic neuritis, in which the dyschromatopsia is much more severe than would be expected for the level of VA.

Causes and Risk Factors

NAION is caused by an infarction (clot/blockage) of the short posterior ciliary arteries, leading to swelling of the optic nerve head. Key risk factors include:

Diagnosis and Prognosis

  • Prognosis: The initial vision loss is usually permanent. The optic disc swelling typically resolves in 1 to 2 months.

female getting eye exam from female doctor used in zepbound and vision loss

Treatment and Management

There is no currently proven effective medical or surgical treatment to reverse the vision loss. Treatment focuses on managing underlying vascular risk factors:

Clinical Research Confirming a Higher Risk of NAION in Patients Taking Zepbound and other GLP-1 Drugs

What Occular Manifestations Zepbound and Other GLP-1 Can Cause

Clinical research and adverse event reporting by patients suggest strongly insinuates that GLP-1 drugs may cause:

Recent studies, particularly from 2024–2025, suggest a possible link between GLP-1 receptor agonists (like Zepbound/Mounjaro [tirzepatide] and Ozempic/Wegovy [semaglutide]) and an increased risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare “eye stroke” causing sudden, permanent vision loss. While the absolute risk remains very low, studies indicate a potential four to sevenfold higher risk for patients with diabetes or obesity.

Key Findings on GLP-1s and NAION

  • Study Data: One published study appearing in JAMA Ophthalmology on July 3, 2024, found a link between GLP-1 and an increased risk of NAION. The study found a higher risk of NAION in patients prescribed GLP-1 compared to those on non-GLP-1 RA medications.
  • Tirzepatide (Zepbound) Findings: While some studies focused on semaglutide, others included tirzepatide (Zepbound), with recent data indicating a potential association with NAION and other optic nerve issues.
  • Inconsistent Evidence: Some studies, including a meta-analysis, did not find a strong correlation, indicating that more research is needed to establish a definitive, direct cause-and-effect relationship.
  • Concerns for Users: Experts advise that patients experiencing sudden, painless vision loss, blurring, or shadowing should seek immediate medical attention.
  • Recent Clinical Investigations: Have identified a concerning association between GLP-1 receptor agonists, including Zepbound (tirzepatide), and elevated rates of NAION.
  • Zepbound NAION Lawsuit:  A landmark study published in 2024 examined medical records from a large ophthalmology practice, revealing statistically significant increases in NAION incidence among patients prescribed these medications for type 2 diabetes and obesity management.
  • Another study established a concerning connection between GLP-1 receptor agonists—including both Zepbound (tirzepatide) and Ozempic (semaglutide)—and increased incidence rates of NAION. Clinical observations have documented elevated occurrences of this condition among patients prescribed these medications compared to individuals using alternative diabetes treatments.

Young girl having eye test eye test machine used in Zepbound and vision loss

Clinical Research and Finding

  • Retrospective Cohort Study (2024):
    • Analyzed data from over 16,000 patients
    • Found a higher incidence of NAION in patients using GLP-1 receptor agonists compared to those on other diabetes medications
    • Reported a hazard ratio of 4.28 for patients with type 2 diabetes and 7.64 for patients with obesity
  • Pharmacovigilance Analysis (2023):
    • Examined adverse event reports submitted to regulatory agencies
    • Identified a disproportionate number of vision-related events associated with GLP-1 receptor agonists
    • Suggested a potential class effect rather than a drug-specific issue
  • Prospective Observational Study (2024):
    • Followed 5,000 patients newly prescribed Zepbound for 18 months
    • Documented a small but statistically significant increase in the incidence of Zepbound vision problems compared to matched controls
    • Noted that risk factors such as hypertension and pre-existing eye conditions may contribute to increased vulnerability to Zepbound vision side effects
  • large Danish registry study also found semaglutide use was associated with higher NAION risk over five years, while NAION remained uncommon overall.

Possible Mechanism

Researchers suggest that the rapid reduction of blood glucose levels caused by these drugs, or potential effects on vascular health, might contribute to rreduced blood flow to the optic nerve, resulting in NAION.

Zepbound and Eye Pain & Inflammation

  • Calls continue to come in with Zepbound eye-pain, blurry vision, floaters, and unfortunatley permanent loss of vision in one eye and a very painful condition, as opposed to diabetic retinopathy, which is usually painless.

Zepbound and Floaters and Retinal Issues

  • Newer reports of floaters (spots or strings in vision) are being investigated as potential signs of retinal detachment or accelerated diabetic retinopathy complications.

High-Value Litigation Terms (Permanent Injury)

  • NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy): Often called an “eye stroke,” this is the core of current Zepbound \vision lawsuits and Trulicity vision loss lawsuitss.. It occurs when blood flow to the optic nerve is blocked, leading to sudden, irreversible blindness.
  • Optic Nerve Damage: Damage to the “cable” connecting the eye to the brain. Unlike some vision issues, this damage typically does not regenerate, meaning the vision loss is permanent.
  • Failure to Warn: The legal basis for most claims. Plaintiffs argue that manufacturers like Eli Lilly (Zepbound/Trulicity) failed to explicitly warn that these drugs could cause permanent blindness or NAION.

close up view of female eye used in zepbound and vision loss

Red Flag” Symptoms:  Zepbound and Sudden Vision Loss

This often occurs upon waking and typically affects only one eye. It is a hallmark symptom of NAION.

Zepbound and Eye Floaters

  • While usually harmless, a sudden increase in floaters or flashes, especially with a dark curtain in vision, requires immediate medical attention to rule out a retinal tear or detachment.

Causes and Risk Factors

  • Posterior Vitreous Detachment (PVD): The primary cause, where the gel-like vitreous shrinks, liquifies, and separates from the retina, common in people aged 40 to 80.
  • Aging: As the body ages, collagen in the vitreous breaks down and clumps, forming floaters, while the shrinkage creates light-producing flashes.
  • Retinal Tear/Detachment: A serious condition where the pulling vitreous tears the retina, requiring immediate treatment to prevent permanent vision loss.
  • Other Factors: Migraines,eye injury/trauma, and inflammation (vitritis) can also cause flashes.

Symptoms

  • Floaters: Specks, dots, threads, or cobwebs that drift in your field of vision, often seen against a bright, blank background.
  • Flashes: Brief, flickering light, sparks, or lightning streaks, typically at the edge of vision.
  • Warning Signs: A sudden, significant increase in floaters, frequent flashes, or a “dark curtain” or shadow covering part of your vision.

Treatment and Management

  • Monitoring: Most, if not all, cases of PVD are harmless, and no specific treatment is required for typical, long-standing floaters.
  • Retinal Evaluation: A dilated eye exam is crucial to determine if the symptoms are benign or indicate a retinal tear, which requires laser therapy or surgery.
  • Lifestyle Adjustments: While no direct treatment exists, reducing dryness with eye drops or wearing sunglasses can make, say, floaters less noticeable.

When to Seek Immediate Care

Consult an eye specialist (optometrist or ophthalmologist) immediately if you experience a sudden onset or spike in floaters, flashes, or a loss of peripheral vision.
  • New Floaters: you notice a lot of new floaters
  • Flashes: you have a lot of flashes
  • Curtain: a gray curtain covers part of your vision
  • Eye Pain or Pressure: While NAION is usually painless, persistent pain or a feeling of “fullness” behind the eye can signal acute glaucoma or severe inflammation.
  • Loss of Color Perception: A new inability to see colors as brightly as before, or colors appearing “washed out” (dyschromatopsia).

These floaters and flashes could be symptoms of a torn or detached retina. This is when the retina pulls away from the back of your eye. This is a serious condition that needs to be treated immediately.

Common Side Effects (Lower Case Value)

  • Zepbound and Blurry Vision / Fluctuating Vision: Vision that shifts from clear to hazy throughout the day. On GLP-1 drugs, this is often a temporary result of rapid blood sugar changes changing the shape of the eye’s lens.
  • Diabetic Retinopathy: Worsening of existing damage to blood vessels in the retina. While serious, many GLP-1 labels already mention this, making “failure to warn” claims more difficult for this specific condition compared to NAION.

Vision Injury Checklist & Definitions

  • Zepbound and Eye Floaters (Vitreous Floaters): Small dark shapes, “spots,” or “cobwebs” that drift across your field of vision. A sudden onset can signal retinal tearing or bleeding caused by rapid eye pressure changes.
  • NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy): Often called an “Eye Stroke.” It is a sudden, painless loss of vision in one eye caused by a lack of blood flow to the optic nerve. This is the “big” permanent injury at the center of 2026 litigation.
  • Zepbound and Blurry Vision: A loss of sharpness that makes it hard to see fine details. While often temporary due to blood sugar shifts, persistent blurring can be a precursor to permanent damage.
  • Flashes of Light (Photopsia): Seeing “lightning streaks” or sparks, especially in your peripheral vision. This is a major warning sign of a retinal detachment.
  • Visual Field Loss: The feeling of a “curtain” or “shadow” falling over part of your vision. This is a medical emergency often linked to optic nerve damage.

Frequently Asked Questions about Zepbound and Vision Loss

What Are the Zepbound Vision Side Effects?

The Zepbound vision side effects include Zepbound and eye twitching, Zepbound dry eye syndrome, eye inflammation, Zepbound and NAION, temporary blurred vision, visual disturbances, eye floaters, and others.

What Causes Zepbound Blindness?

The exact mechanism of how Zepbound can affect your vision is still being investigated.  However, the belief is that Zepbound eye problems may be a result of the side effects caused by the medication.

What Are the Zepbound Vision Side Effects?

While not an exhaustive list, some Zepbound eye problems that may be caused by the medication include Zepbound and blurry visionZepbound and NAION,Zepbound and eye floaters, eye twitching, and inflammation of the eye.

Which Individuals Are at Risk of Developing Zepbound and NAION?

Patients prescribed this medication are at risk of developing Zepbound and NAION, especially if they have a medical history of eye problems, have uncontrolled type 2 diabetes, or are elderly in age.

What Should I Do if I Developed Zepbound Vision Loss or Other Zepbound Eye Problems?

If you have experienced Zepbound eye problems, you should consult with your primary healthcare provider and they call Zepbound vision loss lawyer Timothy L. Miles of the Law Offices of Timothy L. Miles to see if you are eligible for a Zepbound vision loss lawsuit.

Why might someone experience  Zepbound and Sudden Blurry Vision?

Sudden blurry vision after starting Zepbound can result from physiologic changes during early treatment such as blood glucose shifts, dehydration due to gastrointestinal side effects, or other unrelated eye conditions. It’s important to precisely define the symptom since causes vary depending on whether one or both eyes are affected and the speed of onset.

Legal Ad: by Top 100 Trial Lawyer Timothy L. Miles: Contact us today" on contact page, blue and red background and white foreground, used in zepbound and vision loss

If You Suffered from Zepbound Blindness or Other Zepboound Vision Problems, Contact Zepbound Vision Loss Lawyer Timothy L. Miles Today

If you were prescribed Zepbound and took it as directed and suffered Zepbound vision loss or other Zepbound eye problems, contact Zepbound Vision Loss Lawyer Timothy L. Miles today. You could be eligible for a Zepbound vision loss lawsuit and potentially entitled to substantial compensation. (855) 846–6529 or [email protected].

Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com

Facebook  Linkedin  Pinterest  youtube

Logo law office timothy l. miles, a Top 25 Mass Torts lawyer, used in Zepbound zepbound vision loss